Your session is about to expire
← Back to Search
Other
0.003% AR-15512 for Dry Eye Syndrome
Phase 3
Waitlist Available
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported.
* Within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation)
Awards & highlights
Summary
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
Eligible Conditions
- Dry Eye Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, minute 0 (pre-instillation); day 1, minute 3 (post-instillation)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from baseline (pre-drop compared to 3 minutes post-drop) in tear meniscus height (TMH) as measured by optical coherence tomography (OCT)
Trial Design
1Treatment groups
Experimental Treatment
Group I: 0.003% AR-15512Experimental Treatment1 Intervention
One drop in each eye in a staggered cadence (left eye followed by dosing of the right eye) approximately 2-4 hours apart
Find a Location
Who is running the clinical trial?
Alcon ResearchLead Sponsor
719 Previous Clinical Trials
126,384 Total Patients Enrolled
Clinical Trial Lead, PharmaStudy DirectorAlcon Research, LLC
3 Previous Clinical Trials
600 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger